There’s a noticeable surge in the use of weight loss medications like Wegovy, Ozempic, and Mounjaro in Western countries, raising concerns about the sustainability of supply.
However, as these drugs gain traction, scrutiny follows. It’s not just the increasing demand that’s worrying; there are other potential issues at play.
Common gastrointestinal side effects such as nausea, vomiting, and constipation are frequently reported with these GLP-1 receptor agonists. And then there’s the much-discussed “Ozempic face” — a drawn, prematurely aged look that can occur with rapid weight loss.
There are even more serious concerns coming to light, including possible connections to eye diseases, decreased libido, and a potential uptick in certain cancers. It’s worth noting, though, that we’re still in the early stages of understanding these risks, and the evidence remains limited.
One significant cancer-related worry is thyroid cancer. Initial studies on animals indicated that high doses of GLP-1 medications led to thyroid tumors, although definitive proof in humans is still lacking.
That said, a comprehensive French study has suggested a possible association between GLP-1 use and thyroid cancer, particularly in individuals who used the drug for over a year. Due to these findings, it’s advised that people with a personal or family history of thyroid cancer or specific genetic conditions avoid these medications.
There are worries about pancreatic cancer as well, primarily due to some early reports of pancreatitis—an inflammatory condition of the pancreas that can be severe in some cases. Nevertheless, research hasn’t substantiated a direct relationship between GLP-1 drugs and pancreatic cancer.
This issue is crucial to consider because of how these drugs operate.
Wegovy and Ozempic are types of GLP-1 receptor agonists called semaglutide. Initially developed for treating type 2 diabetes, they function by stimulating receptors in the pancreas that increase insulin production while reducing glucagon, a hormone that elevates blood sugar.
These mechanisms help lower blood sugar. The weight loss aspect is tied to the drug’s action on receptors in the brain, gut, and fat cells, which helps reduce appetite.
Mounjaro, which is tirzepatide, takes it a step further by targeting not only the GLP-1 receptor but also the GIP (glucose-dependent insulinotropic polypeptide) receptor.
This dual targeting enhances the pancreas’s insulin production and increases insulin sensitivity, enabling more effective blood sugar regulation. Consequently, Mounjaro may promote greater weight loss than semaglutide alone, making it a standout in obesity treatment.
Notably, clinical trials have not linked tirzepatide to increased cancer risk yet, but it still carries a thyroid cancer warning due to earlier animal studies.
Interestingly, some initial animal studies suggest that tirzepatide could even shrink certain tumors, like those in breast cancer, although it’s early days and not applicable to humans yet.
Obesity is also a cancer risk
It’s essential to remember that obesity is a well-established risk factor for several types of cancer, including breast, colon, liver, and uterine cancers. By aiding significant weight loss and improving metabolic health, GLP-1 drugs might indirectly lower the risk of these diseases.
Indeed, some population studies suggest lower rates of obesity-related cancers among individuals using GLP-1 medications compared to those on other treatments.
However, it remains uncertain if this reduced cancer risk is due to the medications’ effects or merely a byproduct of weight loss. Further research is necessary to clarify this relationship.
The current understanding presents a somewhat reassuring yet uncertain picture. The overall cancer risk linked to GLP-1 medications and tirzepatide seems low.
It’s crucial to stress that these treatments aren’t recommended for individuals with a personal or family background of certain types of thyroid cancer or other endocrine conditions, as these circumstances might heighten susceptibility to hormone-related tumor growth.
While weight-loss injections are not without risks, they also hold significant promise. It’s still unclear whether they represent miracle cures or are just another addition to the ongoing weight loss narrative.
One thing is for sure: the discussion around these medications is far from finished.
They’re altering our perceptions of weight, health, and risks. In the quest to effectively manage weight, they present a blend of hope, science, and a degree of unpredictability amid the excitement.
